Literature DB >> 8879202

Colony growth of human hematopoietic progenitor cells in the absence of serum is supported by a proteinase inhibitor identified as antileukoproteinase.

H M Goselink1, J van Damme, P S Hiemstra, A Wuyts, J Stolk, W E Fibbe, R Willemze, J H Falkenburg.   

Abstract

Serum contains many growth factors and nutrients that stimulate colony formation of hematopoietic progenitor cells (HPC) in semisolid cultures. In the absence of serum, no proliferation of HPCs could be obtained in semisolid medium cultures of partially purified bone marrow cells in the presence of multiple hematopoietic growth factors, insulin, cholesterol, and purified clinical-grade human albumin. This appeared to be due to a suppressive activity induced by monocyte- and T lymphocyte-depleted accessory cells on CD34+ HPCs. Serum-free conditioned medium from the bladder carcinoma cellline 5637 could replace serum to support the growth of HPCs in these cultures. After gel filtration and reverse-phase high-performance liquid chromatography of 5637 supernatants, this activity could be attributed to a 15-kD protein that was further identified by NH2-terminal sequence analysis as the serine proteinase inhibitor antileukoproteinase (ALP). The growth-supportive activity from the 5637 conditioned medium and the (partially) purified fractions could be completely neutralized by a polyclonal rabbit IgG antibody against human ALP (huALP). Similar supportive effects on the growth of HPC could be obtained in the presence of recombinant huALP. We demonstrated that the COOH-terminal domain of ALP containing the proteinase inhibitory activity was responsible for this effect. alpha-1 proteinase inhibitor was capable of similar support of in vitro HPC growth. These results illustrate that proteinase inhibitors play an important role in the in vitro growth of hematopoietic cells by the neutralization of proteinases produced by bone marrow accessory cells. This may be of particular relevance for in vitro expansion of human hematopoietic stem cells in serum-free media.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879202      PMCID: PMC2192846          DOI: 10.1084/jem.184.4.1305

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in human sputum.

Authors:  J A Kramps; C Franken; J H Dijkman
Journal:  Am Rev Respir Dis       Date:  1984-06

Review 2.  Methods for growth of cultured cells in serum-free medium.

Authors:  D Barnes; G Sato
Journal:  Anal Biochem       Date:  1980-03-01       Impact factor: 3.365

3.  Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus.

Authors:  R Heinzel; H Appelhans; G Gassen; U Seemüller; W Machleidt; H Fritz; G Steffens
Journal:  Eur J Biochem       Date:  1986-10-01

4.  The 175 antigen expressed on myeloid and erythroid cells during differentiation is associated with serine protease activity.

Authors:  D Deane; L Inglis; D Haig
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

5.  Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase.

Authors:  R C Thompson; K Ohlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

6.  Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6).

Authors:  J Van Damme; S Cayphas; J Van Snick; R Conings; W Put; J P Lenaerts; R J Simpson; A Billiau
Journal:  Eur J Biochem       Date:  1987-11-02

7.  Influence of plasma protease inhibitors and the secretory leucocyte protease inhibitor on leucocyte elastase-induced consumption of selected plasma proteins in vitro in man.

Authors:  P Björk; L Axelsson; M Bergenfeldt; K Ohlsson
Journal:  Scand J Clin Lab Invest       Date:  1988-04       Impact factor: 1.713

8.  Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture.

Authors:  C A Sieff; S C Ekern; D G Nathan; J W Anderson
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

9.  Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor.

Authors:  J Van Damme; G Opdenakker; R J Simpson; M R Rubira; S Cayphas; A Vink; A Billiau; J Van Snick
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

10.  Transforming growth factor beta 1 is an inducer of erythroid differentiation.

Authors:  G Krystal; V Lam; W Dragowska; C Takahashi; J Appel; A Gontier; A Jenkins; H Lam; L Quon; P Lansdorp
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  3 in total

1.  Serine protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during hematopoietic progenitor mobilization.

Authors:  Ingrid G Winkler; Jean Hendy; Paul Coughlin; Anita Horvath; Jean-Pierre Lévesque
Journal:  J Exp Med       Date:  2005-03-28       Impact factor: 14.307

2.  Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis.

Authors:  Andre M Mueller; Xiomara Pedré; Thomas Stempfl; Ingo Kleiter; Sebastien Couillard-Despres; Ludwig Aigner; Gerhard Giegerich; Andreas Steinbrecher
Journal:  J Neuroinflammation       Date:  2008-05-26       Impact factor: 8.322

3.  CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.

Authors:  Annette Romanski; Christoph Uherek; Gesine Bug; Erhard Seifried; Hans Klingemann; Winfried S Wels; Oliver G Ottmann; Torsten Tonn
Journal:  J Cell Mol Med       Date:  2016-03-23       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.